Toggle Main Menu Toggle Search

Open Access padlockePrints

The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo

Lookup NU author(s): Dr Frida Ponthan, Dr Chris Redfern

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Background. Neuroblastoma, a childhood tumour of the sympathetic nervous system, may undergo spontaneous differentiation or regression due to apoptosis after no or minimal therapy. However, the majority of neuroblastomas are diagnosed as metastatic tumours with a poor prognosis in spite of intensive multimodal therapy. Vitamin A and its analogues (retinoic acid, RA) play an important role in normal cellular differentiation and programmed cell death. RA regulates neuroblastoma growth and differentiation in vitro, and has shown activity against human neuroblastoma in vivo. Procedure, Recently, 9-cis RA was shown to induce apoptosis in vitro in neuroblastoma using a 5 days short-term treatment and subsequent washout. In the present study, nude rats with human neuroblastoma SH-SY5Y xenografts were treated with 13-cis RA (4 mg po daily), 9-cis RA (5 mg po daily) or the novel analogue Ro 13-6307 (0.3 mg po daily) using either a continuous or short-term schedule. Results. All three different retinoids decreased neuroblastoma growth significantly in terms of tumour weight after 8-12 days when compared to untreated controls (P < 0.05). Minor signs of toxicity in 13-cis RA treated rats were observed. However, severe toxicity with significant weight loss was seen in all rats treated with 9-cis RA and Ro 13-6307. Toxicity was more pronounced with the continuous regimen. Conclusions, We conclude that different retinoids reduce neuroblastoma tumour growth in vivo. Drug scheduling and dosage may affect both therapeutic efficacy and toxic side effects. Further in vivo studies are warranted, including pharmacokinetic and molecular analyses, before clinical trials with promising retinoids like 9-cis RA and Ro 13-6307 can be started in children with neuroblastoma. Med. Pediatr. Oncol. 36:127-131, 2001. (C) 2001 Wiley-Liss, Inc.


Publication metadata

Author(s): Ponthan FM, Borgstrom P, Hassan M, Wassberg E, Redfern CPF, Kogner P

Publication type: Article

Publication status: Published

Journal: Medical and Pediatric Oncology

Year: 2001

Volume: 36

Issue: 1

Pages: 127-131

ISSN (print): 0098-1532

ISSN (electronic):

URL: http://dx.doi.org/10.1002/1096-911X(20010101)36:1<127::AID-MPO1030>3.0.CO;2-B

DOI: 10.1002/1096-911X(20010101)36:1<127::AID-MPO1030>3.0.CO;2-B

Notes: Conference: Advances in Neuroblastoma Research: 1998 Conference


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share